The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review

Oscar K Serrano; Charito Love; Inessa Goldman; Kevin Huang; Nicole Ng; Tony Abraham; Raphaella Da Silva; Patricia Friedmann; Steven K Libutti; Timothy J Kennedy

doi:10.1002/jso.24190

Back

The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review

Journal article

Peer reviewed

The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review

Oscar K Serrano, Charito Love, Inessa Goldman, Kevin Huang, Nicole Ng, Tony Abraham, Raphaella Da Silva, Patricia Friedmann, Steven K Libutti and Timothy J Kennedy

Journal of surgical oncology, Vol.113(6), pp.640-646

05/2016

DOI: 10.1002/jso.24190

PMID: 27115836

View Online

Abstract

The value of FDG-PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG-PET before initiating treatment. CT and FDG-PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). We identified 608 patients who had biopsy-proven GA and 207 (34.0%) had a CT and FDG-PET as part of their staging work-up. Of these, imaging from 166 (27.3%) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3%), 84 (50.6%), 25 (15.1%), and 32 (19.3%) patients, respectively; while FDG-PET identified PT, LLN, DLN, and M in 125 (75.3%), 78 (47.0%), 41 (24.7%), and 27 (16.3%) of patients, respectively. FDG-PET up-staged 31 (18.7%) patients while it down-staged 17 (10.2%) patients. Of patients who were up-staged, 20 (64.5%) developed progressive disease. Our findings support the use of FDG-PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9%) patients. J. Surg. Oncol. 2016;113:640-646. © 2016 Wiley Periodicals, Inc.

Adenocarcinoma - diagnostic imaging

Adenocarcinoma - pathology

Adult

Aged

Aged, 80 and over

Female

Fluorodeoxyglucose F18

Follow-Up Studies

Humans

Male

Middle Aged

Neoplasm Staging

Observer Variation

Outcome Assessment (Health Care)

Positron-Emission Tomography - methods

Radiopharmaceuticals

Retrospective Studies

Single-Blind Method

Stomach Neoplasms - diagnostic imaging

Stomach Neoplasms - pathology

Tomography, X-Ray Computed

Details

Title: Subtitle: The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review
Creators: Oscar K Serrano - Albert Einstein College of Medicine
Charito Love - Montefiore Medical Center
Inessa Goldman - Montefiore Medical Center
Kevin Huang - Albert Einstein College of Medicine
Nicole Ng - Albert Einstein College of Medicine
Tony Abraham - Montefiore Medical Center
Raphaella Da Silva - Montefiore Medical Center
Patricia Friedmann - Albert Einstein College of Medicine
Steven K Libutti - Albert Einstein College of Medicine
Timothy J Kennedy - Albert Einstein College of Medicine
Resource Type: Journal article
Publication Details: Journal of surgical oncology, Vol.113(6), pp.640-646
DOI: 10.1002/jso.24190
PMID: 27115836
ISSN: 0022-4790
eISSN: 1096-9098
Language: English
Date published: 05/2016
Academic Unit: Surgery
Record Identifier: 9984322936702771

Metrics

20 Record Views

13 Times Cited - Web of Science

See more details